JARDIANCE (Boehringer Ingelheim Pty Ltd)
Product name
JARDIANCE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
empagliflozin
Registration type
EOI
Indication
Type 2 diabetes mellitus
Glycaemic control
JARDIANCE is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above.